Biosplice Therapeutics, Inc.
🇺🇸United States
A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Registration Number
- NCT03591926
- Locations
- 🇳🇿
Research Site, Dunedin, New Zealand
A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers
Phase 1
Completed
- Conditions
- Tendinopathy
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 223
- Registration Number
- NCT03502434
- Locations
- 🇺🇸
Research Site, Lynchburg, Virginia, United States
A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT03355066
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸UT Health San Antonio - Mays Cancer Center, San Antonio, Texas, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03246399
- Locations
- 🇺🇸
Research Site, Richmond, Virginia, United States
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2017-07-25
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03229291
- Locations
- 🇺🇸
Research Site, Tempe, Arizona, United States
A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 700
- Registration Number
- NCT03122860
- Locations
- 🇺🇸
Research Site, Danville, Virginia, United States
An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis
Completed
- Conditions
- Osteoarthritis
- Interventions
- Other: Not applicable (no therapy is administered as part of this study)
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 703
- Registration Number
- NCT02951026
- Locations
- 🇺🇸
Research Site, Charlottesville, Virginia, United States
A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 455
- Registration Number
- NCT02536833
- Locations
- 🇺🇸
Research Site 1, Saint Louis, Missouri, United States
🇺🇸Research Site 2, Saint Louis, Missouri, United States
🇺🇸Research Site, Franklin, Wisconsin, United States
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
Phase 2
Completed
- Conditions
- Androgenetic Alopecia
- Interventions
- Drug: Topical Vehicle solutionDrug: Topical SM04554 solution
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT02503137
- Locations
- 🇺🇸
Research Site, Lynchburg, Virginia, United States
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 310
- Registration Number
- NCT02275351
© Copyright 2025. All Rights Reserved by MedPath